Advertisement

Systemic Therapy for Advanced Hepatocellular Carcinoma in an Evolving Landscape

  • Kabir Mody
  • Ghassan K. Abou-Alfa
Upper Gastrointestinal Cancers (L Rajdev, Section Editor)
  • 105 Downloads
Part of the following topical collections:
  1. Topical Collection on Upper Gastrointestinal Cancers

Opinion statement

Globally, hepatocellular carcinoma (HCC) is a leading cause of cancer-related death and a malignancy with rising incidence. After sorafenib remaining the one and only FDA-approved therapy for the disease for many years, the past 2 years has seen the landscape of available treatments change dramatically. Multiple multi-targeted tyrosine kinases (TKIs) have demonstrated success and garnered FDA approval both in the first- (lenvatinib) and second-line (regorafenib) settings. Now, various questions regarding the sequencing of these therapies remain for investigation. Effective positioning of these TKIs will be crucial to optimization of outcomes for patients with HCC. Additionally, promising outcomes have been seen with a number of immunotherapies, and one such agent has been approved (nivolumab). Positioning of these immunotherapies in the landscape may or may not have impacts upon sequencing of all of the available therapies. Further studies are ongoing investigating such sequencing questions, in addition to more novel agents to combat this devastating disease.

Keywords

Hepatocellular carcinoma Liver neoplasm HCC Targeted therapy Systemic therapy Tyrosine kinase inhibitors (TKI) Sorafenib Lenvatinib Nivolumab Pembrolizumab Checkpoint inhibitors Cabozantinib Regorafenib Ramicirumab 

Notes

Compliance with Ethical Standards

Conflict of Interest

Kabir Mody has received research funding from Agios, Senwha Biosciences, Taiho, ArQule, Astra Zeneca, Genentech, Incyte, Tracon Pharmaceuticals, Medimmune, and Puma Biotechnology; and has received compensation from AstraZeneca, Bayer, Celgene, Eisai, Exelixis, Merrimack, and Vicus for service as a consultant.

Ghassan K. Abou-Alfa has received research funding from ActaBiologica, Agios, Array, AstraZeneca, Bayer, Beigene, BMS, Casi, Celgene, Exelixis, Genentech, Halozyme, Incyte, Lilly, Mabvax, Novartis, OncoQuest, Polaris Puma, QED, and Roche; has received compensation from 3DMedcare, Agios, Alignmed, Amgen, Antengene, Aptus, Aslan, Astellas, Astra Zeneca, Bayer, Beigene, Bioline, BMS, Boston Scientifc, Bridgebio, Carsgen, Celgene, Casi, Cipla,CytomX, Daiichi, Debio, Delcath, Eisai, Exelixis, Genoscience, Gilead, Halozyme, Hengrui, Inovio, Ipsen, Jazz, Jansen, Kyowa Kirin, LAM, Lilly, Loxo, Merck, Mina, Newlink Genetcis, Novella, Onxeo, PCI Biotech, Pfizer, Pharmacyte, Pharmacyclics, Pieris, QED, Redhill, Sanofi, Servier, Silenseed, Sillajen, Sobi, Targovax, Tekmira,Twoxar, Vicus, Yakult, and Yiviva for service as a consultant; and has patents for articles and methods for preventing and treating dermatologic adverse events issued and licensed.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. 1.
    Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.CrossRefGoogle Scholar
  2. 2.
    Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016;2:16018.CrossRefGoogle Scholar
  3. 3.
    Siegel R, Miller KD, Jemal A. Cancer Statistics, 2018. CA Cancer J Clin. 2018.Google Scholar
  4. 4.
    Bertuccio P, Turati F, Carioli G, Rodriguez T, la Vecchia C, Malvezzi M, et al. Global trends and predictions in hepatocellular carcinoma mortality. J Hepatol. 2017;67(2):302–9.CrossRefGoogle Scholar
  5. 5.
    Collaborators GMaCoD. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117–71.CrossRefGoogle Scholar
  6. 6.
    Nault JC, Datta S, Imbeaud S, Franconi A, Mallet M, Couchy G, et al. Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas. Nat Genet. 2015;47(10):1187–93.CrossRefGoogle Scholar
  7. 7.
    Sorafenib Package Insert and Prescribing Information. 2010.Google Scholar
  8. 8.
    Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64(19):7099–109.CrossRefGoogle Scholar
  9. 9.
    Chang YS, Adnane J, Trail PA, Levy J, Henderson A, Xue D, et al. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol. 2007;59(5):561–74.CrossRefGoogle Scholar
  10. 10.
    Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–90.CrossRefGoogle Scholar
  11. 11.
    Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34.CrossRefGoogle Scholar
  12. 12.
    Abou-Alfa GK. Selection of patients with hepatocellular carcinoma for sorafenib. J Natl Compr Cancer Netw. 2009;7(4):397–403.CrossRefGoogle Scholar
  13. 13.
    Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006;24(26):4293–300.CrossRefGoogle Scholar
  14. 14.
    Giambartolomei S, Covone F, Levrero M, Balsano C. Sustained activation of the Raf/MEK/Erk pathway in response to EGF in stable cell lines expressing the hepatitis C virus (HCV) core protein. Oncogene. 2001;20(20):2606–10.CrossRefGoogle Scholar
  15. 15.
    Huitzil-Melendez FD, Saltz LS, Song J, et al. Retrospective analysis of outcome in hepatocellular carcinoma (HCC) patients (pts) with hepatitis C (C+) versus B (B+) treated with sorafenib (S). Paper presented at: ASCO GI 2007; Orlando.Google Scholar
  16. 16.
    Jackson R, Psarelli EE, Berhane S, Khan H, Johnson P. Impact of viral status on survival in patients receiving sorafenib for advanced hepatocellular Cancer: a meta-analysis of randomized phase III trials. J Clin Oncol. 2017;35(6):622–8.CrossRefGoogle Scholar
  17. 17.
    Ikeda K, Kudo M, Kawazoe S, Osaki Y, Ikeda M, Okusaka T, et al. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma. J Gastroenterol. 2017;52(4):512–9.CrossRefGoogle Scholar
  18. 18.
    •• Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–73 Data regarding the use of Lenvatinib in the management of patients with HCC, and supporting it’s place in the current landscape.CrossRefGoogle Scholar
  19. 19.
    •• Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10064):56–66 The article supporting regorafenib as a therapeutic option for patients with HCC.CrossRefGoogle Scholar
  20. 20.
    •• El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492–502 The final article pertaining to nivolumab’s efficacy and safety in patients with HCC.CrossRefGoogle Scholar
  21. 21.
    Finn R, Merle P, Granito A, et al. Outcomes with sorafenib (SOR) followed by regorafenib (REG) or placebo (PBO) for hepatocellular carcinoma (HCC): results of the international, randomized phase 3 RESORCE trial. J Clin Oncol. 2017;35:344.CrossRefGoogle Scholar
  22. 22.
    Boccaccio C, Comoglio PM. Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer. 2006;6(8):637–45.CrossRefGoogle Scholar
  23. 23.
    Kim JH, Kim HS, Kim BJ, Jang HJ, Lee J. Prognostic value of c-Met overexpression in hepatocellular carcinoma: a meta-analysis and review. Oncotarget. 2017;8(52):90351–7.PubMedPubMedCentralGoogle Scholar
  24. 24.
    Xin Y, Jin D, Eppler S, Damico-Beyer LA, Joshi A, Davis JD, et al. Population pharmacokinetic analysis from phase I and phase II studies of the humanized monovalent antibody, onartuzumab (MetMAb), in patients with advanced solid tumors. J Clin Pharmacol. 2013;53(11):1103–11.CrossRefGoogle Scholar
  25. 25.
    Cecchi F, Rabe DC, Bottaro DP. Targeting the HGF/Met signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012;16(6):553–72.CrossRefGoogle Scholar
  26. 26.
    Lee SJ, Lee J, Sohn I, Mao M, Kai W, Park CK, et al. A survey of c-MET expression and amplification in 287 patients with hepatocellular carcinoma. Anticancer Res. 2013;33(11):5179–86.PubMedGoogle Scholar
  27. 27.
    Kobayashi S, Ueshima K, Moriguchi M, et al. JET-HCC: A phase 3 randomized, double-blind, placebo-controlled study of tivantinib as a second-line therapy in patients with c-Met high hepatocellular carcinoma. ESMO 2017; 2017; Madrid.Google Scholar
  28. 28.
    Cohn A, Kelley RK, Yang T, et al. Activity of cabozantinib (XL184) in hepatocellular carcinoma patients (pts): results from a phase II randomized discontinuation trial (RDT). J Clin Oncol. 2012;30(4s):Abstr 261.CrossRefGoogle Scholar
  29. 29.
    Abou-Alfa G, Meyer T, Cheng A-L, et al. Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: results from the randomized phase III CELESTIAL trial. J Clin Oncol. 2018;36(suppl 4S):abstr 207.CrossRefGoogle Scholar
  30. 30.••
    Abou-Alfa GK, Meyer T, Cheng A-L, el-Khoueiry AB, Rimassa L, Ryoo BY, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018;379(1):54–63 The seminal article on the most recent successful agent in HCC management, thus far.CrossRefGoogle Scholar
  31. 31.
    Zhu AX, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, et al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2015;16(7):859–70.CrossRefGoogle Scholar
  32. 32.
    Harding JJ, El Dika I, Abou-Alfa GK. Immunotherapy in hepatocellular carcinoma: primed to make a difference? Cancer. 2016;122(3):367–77.CrossRefGoogle Scholar
  33. 33.
    Sangro B, Gomez-Martin C, de la Mata M, Iñarrairaegui M, Garralda E, Barrera P, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol. 2013;59(1):81–8.CrossRefGoogle Scholar
  34. 34.
    •• Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer DH, et al. Pembrolizumab (pembro) in patients with advanced hepatocellular carcinoma (HCC): KEYNOTE-224 update. J Clin Oncol. 2018;36. Up to date data on the efficacy of Pembrolizumab in the management of HCC.:4020.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Mayo Clinic Cancer CenterMayo Clinic FloridaJacksonvilleUSA
  2. 2.Memorial Sloan Kettering Cancer CenterNew YorkUSA
  3. 3.Weill Cornell Medical CollegeNew YorkUSA

Personalised recommendations